Erasca (NASDAQ:ERAS) Price Target Raised to $20.00 at Bank of America

Posted by Stanley Muller on Aug 15th, 2026

Erasca (NASDAQ:ERAS – Free Report) had its target price increased by Bank of America from $18.00 to $20.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other research analysts have also recently weighed in on ERAS. Wolfe Research set a $16.00 target price on shares of Erasca in a research note on Thursday, June 4th. Wall Street Zen cut shares of Erasca from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright upped their price objective on Erasca from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday. Jefferies Financial Group restated a “buy” rating on shares of Erasca in a research note on Tuesday, July 14th. Finally, Stifel Nicolaus boosted their price target on shares of Erasca from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Erasca has a consensus rating of “Moderate Buy” and a consensus price target of $22.09.

Get Our Latest Analysis on Erasca

Erasca Price Performance

Shares of Erasca stock opened at $18.38 on Friday. The firm has a market cap of $6.43 billion, a PE ratio of -19.35 and a beta of 0.66. Erasca has a 1 year low of $1.33 and a 1 year high of $24.28. The stock has a fifty day moving average price of $17.31 and a 200-day moving average price of $15.02.

Erasca (NASDAQ:ERAS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, equities analysts anticipate that Erasca will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its position in Erasca by 58.0% during the second quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock worth $27,000 after buying an additional 7,923 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Erasca in the 2nd quarter valued at about $29,000. Russell Investments Group Ltd. purchased a new stake in shares of Erasca in the 3rd quarter valued at about $31,000. Allworth Financial LP bought a new stake in shares of Erasca during the 2nd quarter valued at about $34,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Erasca during the 4th quarter valued at about $38,000. Institutional investors own 67.78% of the company’s stock.

Erasca News Summary

Here are the key news stories impacting Erasca this week:

Positive Sentiment: HC Wainwright maintained its Buy rating and $22 price target, implying additional upside from the stock’s recent trading level. The target supports the bullish view that Erasca’s development pipeline could drive further appreciation. HC Wainwright Increases Erasca Price Target to $22.00
Neutral Sentiment: Bank of America raised its price target from $18 to $20 but retained a Neutral rating. The higher target is supportive, but the unchanged rating indicates the bank views the shares as fairly valued relative to near-term risks. Bank of America Raises Erasca Price Target
Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026 through 2030, including estimates of losses of $0.51 per share for 2026, $0.58 for 2027, $0.61 for 2028, $0.70 for 2029 and $0.54 for 2030. It also reduced its third- and fourth-quarter 2026 loss estimates to $0.14 and $0.15 per share, respectively. The revisions suggest expectations for profitability remain distant, despite the firm’s Buy rating and $22 target. HC Wainwright Erasca Earnings Estimate Revisions

Erasca Company Profile

(Get Free Report)

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.